NCBiotech News

The North Carolina Economic Development Association today honored the North Carolina Biotechnology Center's Laura Rowley, Ph.D., as the Emerging Leader of the Year for her successes in attracting and retaining life sciences companies.

Raleigh ag tech company Genoverde Biosciences has shifted focus during COVID-19, using its facilities and tech to provide hand sanitizers to communities in need.

Holly Springs biotech startup Avior Bio says its Phase 1 clinical trial shows its chronic itch therapy is “safe and tolerable.”

Gene therapy pioneer AskBio of Chapel Hill, supported in its early years by NCBiotech, will be acquired by Bayer AG, the German healthcare and ag conglomerate, for up to $4 billion.

Durham's Tellus Therapeutics has received Orphan Drug and Rare Pediatric Drug designations from the FDA for its neonatal brain injury treatment.

Durham's Emergo has just received $3.5 million in equity backing from 77 investors for a new clinical study to see how the therapy works on patients with flu-like symptoms.

Burlington-based LabCorp has launched a new antibody test for research labs, the latest in a string of contributions to the fight against SARS-CoV-2, the virus that causes COVID-19.

MED-EL Medical Electronics, a hearing-technology company with U.S. headquarters in Durham, was recently named “Innovator of the Year” by the online publication Hearing Health & Technology Matters.

Scientists now have a complete genetic blueprint to help them better understand the western flower thrips and to find ways to control the pest.

Any STEM company in North Carolina that has received a specified type of federal grant for research and development has until Dec. 1 to apply for matching state funds through the One NC Small Business Program.

Shattuck Labs is changing the face of cancer therapy, aided by a $202 million IPO and equity funding that will push its clinical research on cancer immunotherapy to the next level.

North Carolina’s 30-year investment in the life sciences is paying off by creating great jobs and revenue for the state, according to a new report from the Battelle Technology Partnership Practice.

Amanda Taylor, a 29-year veteran of Merck, assumed responsibility for the Maurice R. Hilleman Center for Vaccine Manufacturing in Durham.on August 1.

The Maurice R. Hilleman Center for Vaccine Manufacturing in Durham, where yet another 100-job expansion was announced this week, is key to Merck’s future as one of the world’s powerhouse vaccine manufacturers.